Share this page | Email | Contact Us

Special Report on

Prescription Drug Marketing

prescription drug marketing special research report Photo by www.mydochub.com
      The pharmaceutical industry in the United States has emerged as one of the most lucrative and influential industries in recent history.  Since 1997 we have witnessed the birth of direct-to-consumer (DTC) marketing of prescription drugs through nearly every media stream available.  Depression, anxiety, diabetes, and arthritis are among the most highly advertised conditions.  Corporate giants in the industry compete for a greater market share for medicating each illness; relentlessly driving delusive information down the consumer’s throat in a thirty second T.V. spot. The mass marketing of prescription ...
Evidences show that marketing practices can negatively affect both patients and the health care profession. Many countries have measures in place to limit advertising by pharmaceutical companies . Pharmaceutical company spending on marketing far exceeds that spend on research. 1 In Canada, $1.7 billion was spent in 2004 to market drugs to physicians; in the United States, $21 billion was spent in 2002. 2 In 2005 money spent on pharmaceutical marketing in the US was estimated at $29.9 billion with one estimate as high as $57 billion. 1 When the US number are broken down 56% was free samples, 25% was detailing of physicians, 12.5% ...
REVIEWS AND OPINIONS
Why Prescription Drug Marketing Leads to Expensive Health ...
There are many factors that affect the price of health insurance plans. Increasing medical costs play a major role in that. One of the primary drivers of those costs are prescription drugs. As medications are developed and improved for more conditions, patients and doctors can benefit. However, pharmaceutical companies are earning billions of dollars in profit each year at the expense of access to cost-effective health insurance plans. The United States is one of two countries in the world (the other is New Zealand) which allows direct-to-consumer advertising of prescription drugs. Medications are marketed like any other ... market research, surveys and trends
Big Pharma Research Cost Defense of High Drug Prices Debunked in ...
Readers may know I have perilous little sympathy for Big Pharma. The industry too often wraps itself in the mantle of science, in particular, claiming its needs its high profits and hence high prices to support its research and development efforts. In fact, it spends more on marketing than on R&D (and perilous few industries sell products with fat enough margins to support the cost of frequent sales calls to small businesses, let alone prime time TV ads). And it is a given that it allocates as much overhead as its accountants will tolerate to its reported R&D levels. A new and interesting line of attack has ... market research, surveys and trends

SURVEY RESULTS FOR
PRESCRIPTION DRUG MARKETING

TAP Pharmaceuticals settles Medicare fraud case for $875 million
TAP Pharmaceuticals will pay $875 million to settle claims that it paid kickbacks to doctors to promote Lupron, the company's prostate cancer drug, and cheat Medicare by filing false claims. Prescription drugs are typically not covered by Medicare. However, Lupron — which is injected in the doctor's office — is covered under Medicare as a cancer treatment. TAP, a joint venture of Abbott Laboratories of Illinois and Takeda Chemical Industries of Japan, has also reached an agreement with federal prosecutors in Boston to plead guilty to a criminal charge of violating the federal Prescription Drug Marketing Act. industry trends, business articles and survey research
Compliance Week: Survey: How Mature Is Your Compliance Function?
hief compliance officers apparently still have lots of work ahead to turn their compliance efforts into strong, mature programs that can handle the broad range of risks corporations face. That’s according to the findings of a joint study conducted by Compliance Week and Paisley, which polled 386 compliance, legal, and audit executives on the subject. The survey quizzed executives about how mature their compliance functions are, what processes they use to manage specific risks, and more. Overall, a plurality of respondents (44 percent) described their compliance function as “organized but reactive”—that ... industry trends, business articles and survey research
RELATED NEWS
Pharmaceutical websites could be misleading
Prescription drug websites are under-regulated by the Food and Drug Administration and may cause confusion or mislead consumers, according to a recent study by the University of Minnesota and Dartmouth University. Jon Schommer, associate head of the University’s department of pharmaceutical care and health systems, and Dartmouth linguistics professor Lewis Glinert, examined the websites of the 100 best-selling prescription drugs and found a surprising lack of consistency when it came to advertising standards. Many of the websites displayed an unpredictable mix of information, promotion, content, verbal style, visuals and ... market trends, news research and surveys resources
RX DRUG ABUSE: Addiction programs see bigger caseloads
Prescription drug abuse has gotten additional attention from area law enforcement in the past several months, and that has translated to larger caseloads for drug counselors. Ongoing efforts to combat addiction and the illegal sale of prescription drugs, particularly painkillers, led community and law enforcement leaders in Allen County to form a prescription drug forum last year. In Warren County, the Bowling Green-Warren County Drug Task Force launched an investigation that resulted in the arrest of a former pharmacy employee at The Medical Center who was accused of contributing to the illegal drug market. Amanda Herndon, of ... market trends, news research and surveys resources

INFORMATION RESOURCES

Prescription Drug Marketing
Prescription Drug Marketing: What Consumers Need to Know. What Consumers Need to Know ... Prescription Drug Marketin. Prescription Drug Marketing—page 2 ... technology research, surveys study and trend statistics
CPG Sec. 160.900 Prescription Drug Marketing Act -- Pedigree ...
This document is intended to clarify for FDA personnel and the regulated industry how the agency intends to prioritize its enforcement efforts regarding the pedigree requirements in 21 U.S.C. 353(e)(1)(A) and 21 CFR Part 203 during the first year after the effective date of 21 CFR §§ 203.3(u) and 203.50. FDA’s guidance documents, including this CPG, do not establish legally enforceable rights or responsibilities. Instead, guidance documents describe the agency’s current thinking on a topic and should be viewed only as recommendations, unless specific regulatory or statutory requirements are cited. The use of the word should in ... technology research, surveys study and trend statistics
Drug Marketing - Annals of Health Law Wiki - Loyola University ...
Prescription Drug Marketing refers to the promotion, branding, labeling, advertising, and pricing of prescription medications. The [Prescription Drug Marketing Act of 1987] provides the regulatory framework for the sale, marketing, packaging, and distribution of prescription drugs. The [Federal Food, Drug, and Cosmetic Act] codified the statutory framework, and was significantly updated by the [Food and Drug Administration Modernization Act of 1997] . 1 Separate guidelines apply to the marketing of [over-the-counter] medicines. The advertising of prescription drugs is generally aimed at two ...
REAL TIME
PRESCRIPTION DRUG MARKETING
QUESTIONS AND ANSWERS
WikiAnswers - Who regulates the prescription distribution ...
The National Coalition of Pharmaceutical Distributors (NCPD) strongly advocates a new approach to ensuring the safety of pharmaceutical distribution in the United States. Several members of NCPD were party to a suit in the Eastern District (New York) Federal Court, which resulted in a temporary injunction against FDA over so-called "pedigree" rules, which has been its method of preventing counterfeit pharmaceutical products from entering the supply chain. The problem, NCPD contends, is that FDA's rules, as written, would have left wide swaths of the supply chain unregulated and unmonitored, and would have resulted ...
What ethical issues were involved in TAP Pharmaceuticals? - Yahoo ...
TAP Pharmaceuticals had a lack of in-house legal counsel and a culture where only numbers mattered were just a few of the unethical practices at TAP. Physicians were bribed with an administration fee for prescribing TAP’s new drug Lupron, were given samples at a discounted price or for free, and even told to charge Medicare full price and keep the difference. Big screen televisions, boats, and second homes were also incentives the urologists received from administering this new drug, as well as office equipment and golf vacations. Representatives were not keeping track of the free samples given away which is required by law. ...